FLC Capital Advisors Takes Position in GSK plc (NYSE:GSK)

FLC Capital Advisors bought a new stake in GSK plc (NYSE:GSK) during the 4th quarter, HoldingsChannel.com reports. The fund bought 8,238 shares of the pharmaceutical company’s stock, valued at approximately $279,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Eastern Bank acquired a new position in shares of GSK in the third quarter valued at about $26,000. ST Germain D J Co. Inc. boosted its position in GSK by 195.5% in the fourth quarter. ST Germain D J Co. Inc. now owns 789 shares of the pharmaceutical company’s stock valued at $27,000 after buying an additional 522 shares during the last quarter. Sunbelt Securities Inc. increased its holdings in GSK by 73.8% in the 3rd quarter. Sunbelt Securities Inc. now owns 711 shares of the pharmaceutical company’s stock worth $29,000 after buying an additional 302 shares during the period. Concord Wealth Partners raised its position in GSK by 231.8% during the 3rd quarter. Concord Wealth Partners now owns 783 shares of the pharmaceutical company’s stock worth $32,000 after buying an additional 547 shares during the last quarter. Finally, Fortitude Family Office LLC acquired a new stake in GSK during the 3rd quarter valued at approximately $42,000. Hedge funds and other institutional investors own 15.74% of the company’s stock.

Wall Street Analyst Weigh In

GSK has been the subject of several recent research reports. Deutsche Bank Aktiengesellschaft cut shares of GSK from a “buy” rating to a “hold” rating in a report on Friday, November 15th. Jefferies Financial Group lowered GSK from a “buy” rating to a “hold” rating and reduced their price objective for the company from $53.00 to $39.50 in a research note on Tuesday, November 12th. Guggenheim downgraded GSK from a “buy” rating to a “neutral” rating in a research note on Thursday, October 31st. Finally, StockNews.com upgraded GSK from a “buy” rating to a “strong-buy” rating in a research report on Monday, January 13th. Seven investment analysts have rated the stock with a hold rating and four have issued a strong buy rating to the stock. Based on data from MarketBeat.com, GSK has an average rating of “Moderate Buy” and a consensus target price of $43.25.

GSK Price Performance

NYSE:GSK opened at $33.46 on Monday. The stock has a market capitalization of $69.34 billion, a PE ratio of 21.72, a price-to-earnings-growth ratio of 1.44 and a beta of 0.63. GSK plc has a 52 week low of $31.72 and a 52 week high of $45.92. The company has a quick ratio of 0.53, a current ratio of 0.81 and a debt-to-equity ratio of 0.98. The stock’s 50-day moving average price is $34.02 and its 200-day moving average price is $37.98.

GSK Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, January 9th. Stockholders of record on Friday, November 15th were given a $0.3928 dividend. The ex-dividend date was Friday, November 15th. This is a boost from GSK’s previous quarterly dividend of $0.38. This represents a $1.57 dividend on an annualized basis and a dividend yield of 4.70%. GSK’s payout ratio is 96.10%.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.